Friend virus-induced erythroleukemias of mice have provided an excellent model system for analysing the multistep process of leukemogenesis (for reviews, see Ben-David and Bernstein, 1991) . The murine erythroleukemia (MEL) cell lines which can be established from such mice also oer the opportunity to investigate the events associated with terminal dierentiation and re-establishment of controlled cell division by tumor cells. MEL cells are transformed erythroid precursors that are blocked at about the proerythroblast stage of dierentiation (Friend et al., 1971) . Treatment of the cells with a variety of lowmolecular-weight compounds, including dimethylsulfoxide (DMSO) and hexamethylene bisacetamide (HMBA), causes them to reenter a dierentiation program culminating in terminal cell division and accumulation of hemoglobin and other erythrocytespeci®c proteins .
Friend virus consists of a complex of two retroviruses: the replication-defective spleen-focus forming virus (SFFV) and a replication-competent, helper Friend murine leukemia virus (for a review, see . The erythroleukemia produced in Friend virus-infected animals is a multistage disease. To date, three events have been identi®ed which contribute to generation of malignant erythroid cells (for a review, see Ben-David and Bernstein, 1991) . The early stages of this process are associated with a polyclonal proliferation of nonleukemic erythroid progenitors caused by interaction of the SFFVencoded 55 kd fusion glycoprotein (gp55) with the erythropoietin receptor (Hoatlin et al., 1990; Li et al., 1990; Casadevall et al., 1991) . Subsequently, clonal or oligoclonal erythroleukemic cells emerge. In most cases these malignant cells have suered two additional genetic events: inactivation of p53 (Rovinski et al., 1987; Ben-David et al., 1990; Munroe et al., 1990) and SFFV proviral insertions at the Spi-1 locus which encodes the PU.1 transcription factor (MoreauGachelin et al., 1988; Paul et al., 1989 Paul et al., , 1991 Goebl, 1990) .
PU.1 is a member of the Ets family of transcription factors (Klemsz et al., 1990) . It is expressed speci®cally in hematopoietic cells, especially in cells of the monocytic and B lymphoid lineages (Klemsz et al., 1990; Galson et al., 1993) . Inactivation of the PU.1 gene in mice by gene targeting revealed that PU.1 is required for development of multiple hematopoietic lineages, including B and T lymphocytes, monocytes and granulocytes. However, it does not appear to be necessary for production of fetal megakaryocytes or erythroid progenitors, although it may function during later stages of fetal erythroblast maturation (Scott et al., 1994) . Consistent with the observation that PU.1 gene expression is activated in most SFFV-generated erythroleukemias, Schuetze et al. (1993) reported that a PU.1-encoding retrovirus is capable of eciently immortalizing erythroblasts from infected long-term bone marrow cultures. Interestingly, two other ets family genes,¯i-1 and v-ets, have also been implicated in erythroleukemic transformation (Nunn and Hunter, 1989; Ben-David et al., 1991; Metz and Graf, 1991) . These results suggest that deregulated expression of PU.1, and possibly other ets family genes, interferes with processes required for terminal dierentiation of erythroblasts. To investigate the role of PU.1 in terminal erythroid dierentiation, we analysed MEL cells transfected with a PU.1 cDNA driven by heterologous gene expression control elements. The results indicate that deregulated expression of PU.1 can block chemically-induced dierentiation and terminal cell division of MEL cells. Analysis of PU.1 transfected MEL cells and other MEL transfectants which are blocked from dierentiating due to the presence of exogenous copies of c-myc or c-myb suggests that PU.1 acts upstream of these two protooncogenes in inhibiting MEL cell dierentiation.
Expression of PU.1 is down regulated as MEL cells commit to terminal dierentiation
Chemically induced dierentiation of MEL cells leads initially to the production of cells that are not overtly dierentiated but that are irreversibly committed to dierentiate. These committed cells, which no longer require the presence of the inducing agent to execute the terminal dierentiation and terminal cell division programs, ®rst appear 12 ± 24 h after initiation of inducer treatment, depending on conditions (Gusella et al., 1976) . Upon exposure to inducer, the levels of cmyc and c-myb mRNAs decline rapidly and then are reexpressed to nearly preinduction levels at about 24 h, followed by a second decline as cells undergo dierentiation (Lachman and Skoultchi, 1984; Ramsay et al., 1986) . High level expression of transfected copies of either c-myc or c-myb in MEL cells markedly inhibits dierentiation and there is evidence that these eects are due to the increase in Myc or Myb levels after 24 h during the second decline in the expression of the two endogenous genes (Coppola and Cole, 1986; Dmitrovsky et al., 1986; Lachman et al., 1986; Prochownik and Kukowska, 1986; Clarke et al., 1988; McClinton et al., 1990) . Previous studies have shown that PU.1 expression is reduced in dierentiating MEL cells (Schuetze et al., 1992; Galson et al., 1993; Delgado et al., 1994) . To determine the kinetics of PU.1 down regulation in relation to cell commitment to terminal dierentiation, we measured PU.1 mRNA levels by a RNase protection assay (Figure 1a ), PU.1 protein levels by immunoblotting ( Figure 1b Clone DS19 MEL cells were grown in Dulbecco's modi®ed Eagle medium (DME) supplemented with 10% fetal bovine serum as described previously (Cheng and Skoultchi, 1989) in the presence of 5 mM HMBA. At the times indicated, total cellular RNA was prepared by hot-phenol extraction at 608C (Soeiro and Darnell, 1969) and 20 mg of RNA were analysed by a RNase protection assay (Dong et al., 1995) for PU.1 mRNA or by Northern blot hybridization (Sambrook et al., 1989) for c-myc mRNA. A 448 nt 32 P-CTP-labeled antisense RNA probe synthesized with SP6 RNA polymerase from a SacI/PstI subclone of PU.1 cDNA in pGEM3Z was used in the RNase protection assay. A 780 bp PstI/XhoI fragment of c-myc cDNA derived from pMcmyc54 (Stanton et al., 1983) was labeled with [a- (Harlow and Lane, 1988) at the indicated times. 25 mg of protein were analysed by immunoblotting (Harlow and Lane, 1988 ) using a 1 : 300 dilution of polyclonal anti-PU.1 antibody (Delgado et al., 1994 kindly provided by F Moreau-Gachelin) as the primary antibody and a 1 : 2000 dilution of horse radish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Biorad) as the secondary antibody. HRP activity was detected with the ECL system (Amersham). The size of the PU.1 protein (approximately 40 kDa) agrees with previously published reports (Schuetze et al., 1992; Delgado et al., 1994) . (c) The autoradiograms shown in (a) and (b) were scanned with a Molecular Dynamics densitometer and quanti®ed using the ImageQuant software program. The intensities of the protected 237nt PU.1 RNA fragment and the PU.1 protein at the indicated times were determined relative to those obtained from untreated (0 h) cells which were assigned a value of 100. c-myc mRNA hybridization intensities were normalized to the intensities of hybridization with a 28S rRNA probe in each lane and Myc mRNA levels were calculated relative to that obtained with RNA from untreated (0 h) cells which was assigned a value of 100. Cell commitment to terminal dierentiation was determined by plasma clot assay (McLeod et al., 1974) . Brie¯y, MEL cells treated with HMBA for the times indicated were plated in plasma clots at 100 ± 200 cells/well in microtiter plates without HMBA. After incubation for 4 days, plasma clots were transferred to slides, ®xed with glutaraldehyde and stained with benzidine and hematoxylin. Percent committed cells were calculated from the fraction of colonies containing 532 cells that stained positive with benzidine is not comparable to the reexpression of c-myc and cmyb mRNAs to nearly preinduction levels occurring at these times (Lachman and Skoultchi, 1984; Kirsch et al., 1986 and Figure 1a) . In general, PU.1 protein levels paralleled its mRNA levels including exhibiting a small increase at 12 h of HMBA treatment. However, the magnitude of the decline in PU.1 protein levels was not as great as that of the mRNA. By 24 h of HMBA treatment when about 35% of the cells had committed to terminal dierentiation, PU.1 had declined to about 35% of preinduction levels. Thereafter PU.1 protein levels declined as additional cells committed. These results show that the decline of PU.1 expression occurs prior to the second decline in c-myc and c-myb expression and that it is closely linked in time to cell commitment.
Deregulated expression of the PU.1 gene blocks MEL cell commitment and dierentiation
To determine whether down regulation of PU.1 gene expression is required for MEL cell dierentiation we transfected the cells with a PU.1 cDNA under control of the human elongation factor EF1a promoter in plasmid pEBB ( Figure 2a ). The EF1a promoter is highly active in stimulating transcription of heterologous genes in a variety of mammalian cell lines (Mizushima and Nagata, 1990) . Cells were cotransfected with pEBB-PU.1 and pPGKneo (McBurney et al., 1991) by lipofection and transfectants were selected in Geneticin (G418). We also cotransfected MEL cells with pPGKneo and a construct in which the PU.1 cDNA was placed in the antisense (AS) orientation relative to the EF1a promoter. Cotransfectants expressing either EF1a ± PU.1 mRNA or EF1a ± AS-PU.1 RNA were identi®ed by RNase protection assays using riboprobes complementary to the two EF1a ± PU.1 chimeric RNAs (Figure 2b ). Of 48 G418 resistant clones also transfected with pEBB-PU.1, 13 clones were found to express detectable levels of EF1a ± PU.1 mRNA, whereas from 30 G418 resistant clones cotransfected with pEBB-AS-PU.1 nine clones expressed detectable levels of the PU.1 antisense RNA.
The RNase protection assay used to detect EF1a ± PU.1 chimeric mRNA also permits detection of endogenous PU.1 mRNA which produces a smaller sized protected fragment (207 nt vs 155 nt, Figure 2b ). This feature allowed us to estimate the level of EF1a ± PU.1 mRNA relative to endogenous PU.1 mRNA. Six transfectants expressing levels of EF1a ± PU.1 mRNA equal to or greater than that of endogenous PU.1 mRNA were identi®ed. The levels of EF1a ± PU.1 mRNA in these clones were 100 ± 165% of the levels of endogenous PU.1 mRNA (Figure 2c and data not shown). In addition four clones expressing high levels of EF1a ± AS-PU.1 antisense RNA were identi®ed. These clones produced levels of antisense RNA which exceeded the level of endogenous PU.1 mRNA. Nevertheless, these clones do not appear to have reduced levels of endogenous PU.1 mRNA (data not shown).
As shown in Figure 1 , HMBA treatment of MEL cells results in a rapid decline in PU.1 mRNA level such that only a very low level of the mRNA is present in cells after 8 h. To determine whether the expression of the transfected EF1a ± PU.1 gene was refractory to inducer treatment, EF1a ± PU.1 mRNA levels were measured during HMBA treatment of transfectants by RNase protection assay. Figure 2d shows the EF1a ± PU.1 mRNA levels were initially reduced by a small extent with HMBA treatment but by 24 h of exposure to HMBA, mRNA levels were restored to pretreatment values. Even though EF1a ± PU.1 mRNA levels were reduced slightly at 12 h the levels were considerably higher than that of endogenous PU.1 mRNA in 12 h inducer-treated MEL cells (Figure 2d) . Interestingly, we observed in several EF1a ± PU.1-expressing transfectants that endogenous PU.1 mRNA levels also were refractory, to varying extents, to HMBA treatment (Figure 2d ). This eect was not seen in clones that failed to express the transfected EF1a ± PU.1 gene. At present we do not understand this phenomenon. The eect is reminiscent of previous observations with deregulated c-myc and c-myb MEL transfectants in which the response of endogenous c-myc and c-myb genes to inducer treatment was altered in the respective transfectants relative to the usual response seen in untransfected MEL cells (Coppola and Cole, 1986; Dmitrovsky et al., 1986; Lachman et al., 1986; Prochownik and Kukowska, 1986; Clarke et al., 1988; Todokoro et al., 1988; McClinton et al., 1990) .
We also measured PU.1 protein levels by immunoblotting of extracts from transfectants treated with HMBA. HMBA treatment of the parental MEL cells causes a decrease in PU.1 to very low levels by 36 h (Figures 1 and 2e) . In contrast, the PU.1 content of transfectants was maintained at a high level during HMBA treatment (Figure 2e ) and these levels were unchanged even after 120 h of HMBA treatment (data not shown). Although it is not possible to distinguish the endogenous PU.1 from that produced by the EF1a ± PU.1 construct, it is apparent that transfection with the construct results in maintenance of PU.1 at high levels during HMBA treatment.
To determine whether the deregulated expression of the transfected EF1a ± PU.1 gene interfered with MEL cell dierentiation, the six clones expressing the highest levels of EF1a ± PU.1 mRNA, as well as four transfectants expressing high levels of EF1a ± PU.1 antisense RNA, were analysed for their capacity to dierentiate in response to HMBA. Four G418-resistant transfectants which failed to express EF1a ± PU.1 mRNA were used as additional controls. As shown in Table 1 , all six transfectants expressing EF1a ± PU.1 mRNA exhibited markedly reduced capacity to dierentiate and produce benzidinepositive, hemoglobinized cells after 3 and 5 days of HMBA treatment. These clones also failed to accumulate large quantities of b-globin mRNA (Figure 3a) . Production of benzidine-positive cells also was strongly inhibited in these lines treated with HMBA for 8 days, indicating that dierentiation was not simply delayed by deregulated PU.1 gene expression. In contrast, the transfectants that did not express EF1a ± PU.1 mRNA, as well as the clones expressing antisense PU.1 mRNA, all dierentiated well in response to HMBA.
Although transfectants expressing EF1a ± PU.1 mRNA were strongly inhibited for HMBA-induced accumulation of globin mRNA and hemoglobinized cells, we noted that their growth rate in the presence of HMBA was reduced signi®cantly compared with to +912 relative to ATG). The PCR-generated DNA fragment was treated with Klenow polymerase and cloned into the SmaI site of pGEM3Z to yield pGEM-PU.1. The sequence of the insert agreed with the published PU.1 cDNA sequence (Klemsz et al., 1990) . A 960 bp PU.1 cDNA fragment derived from pGEM-PU.1 was inserted into the BamHI site of pEBB, a modi®ed version of pEBOS (Mizushima and Nagata, 1990 kindly provided by D Baltimore's laboratory), in the sense (unbroken arrow) and antisense (broken arrow) orientations giving rise to pEBB-PU.1 and pEBB-AS-PU.1, respectively. The promoter, exon 1, intron 1 and exon 2 of the EF1a gene and the 3' untranslated (UT) region containing the polyadenylation signal (PAS) of the human G-CSF gene in pEBB are indicated. Restriction enzyme sites: Ng, NgoMI; Na, NarI; B, BamHI; Ns, NsiI. (b) Strategy for analysing endogenous and exogenous PU.1 transcripts in transfected cells by RNase protection assays. pGES was constructed by inserting a 678 bp NgoMI/NsiI fragment from pEBB-PU.1 into XmaI/PstI digested pGEM3Z. Analysis of endogenous and exogenous PU.1 transcripts in pEBB-PU.1 MEL cell transfectants was performed with a 458 nt riboprobe synthesized with SP6 RNA polymerase from NarI-digested pGES. Antisense PU.1 transcripts in pEBB-AS-PU.1 transfectants were detected with a 658 nt riboprobe synthesized with T7 RNA polymerase from HindIII-digested pGES. (c) Detection of PU.1 transcripts in MEL cell transfectants. For DNA transfection, exponentially growing cells were centrifuged, washed twice in DME medium, and resuspended at a density of 10 7 cells/ml in DME medium. 75 mg of pEBB-PU.1 or pEBB-AS-PU.1 and 0.5 mg of pPGKneo (McBurney et al., 1991) were mixed in 0.3 ml DME medium and added to 0.3 ml DME medium containing 50 ml of lipofectin (GIBCO-BRL). The DNA-lipid mixture was incubated for 15 min at room temperature, and then added to 0.5 ml of cell suspension in a cell culture¯ask. After incubation at 378C for 6 h, the cell suspension was diluted to 10 4 ± 10 5 cells/ml with prewarmed complete growth medium and distributed to 96-similarly treated MEL cells and the control and antisense RNA expressing transfectants. This observation raised the possibility that terminal cell division might be occurring in these clones and that processes that determine commitment might be uncoupled from the expression of terminal dierentiation traits. To ascertain whether or not terminal cell division actually occurred in pEBB-PU.1 transfectants, plasma clot assays were performed on three transfectants expressing EF1a ± PU.1 mRNA (clones 605, 1103, 1112) as well as on MEL cells, a pEBB ± PU.1 transfectant that did not express EF1a ± PU.1 mRNA (clone 615) and a transfectant expressing EF1a ± AS-PU.1 antisense RNA (clone 1309). In these experiments cells were treated for various times with HMBA in liquid culture and then removed from HMBA-containing medium and plated in plasma clots in the absence of HMBA. Usually after 4 days of incubation in plasma clots, the clots were ®xed and stained with benzidine reagent. Cells committed to terminal dierentiation by prior exposure to HMBA gave rise to small (532 cells) colonies in which all cells were benzidine-positive, whereas uncommitted cells produced large, benzidinenegative colonies. Consistent with the liquid culture analyses shown in Table 1 , pEBB-PU.1 transfectants produced very few benzidine-positive colonies even after 6 days of HMBA treatment, whereas nearly all cells of the control cell lines produced benzidinepositive colonies after 2 days in HMBA (Figure 3b) . Furthermore, in agreement with the slow-growth in liquid culture, we noted that after 4 days of incubation in plasma clots many of the colonies produced from the three transfectants treated with HMBA for 24 h or longer (e.g. 30% after 48 h of induction) were quite small (532 cells per colony). This result suggested that these transfectants might indeed produce committed cells with delayed commitment kinetics in response to HMBA. Therefore to determine whether these small colonies had indeed undergone terminal cell division, the plasma clots were incubated for up to 9 days. With increasing incubation times in plasma clot nearly all cells gave rise to colonies consisting of hundreds of cells, similar in size to that produced by uncommitted cells. The results indicate that deregulated expression of the PU.1 gene blocks both the commitment to terminal cell division and expression of dierentiated traits. However, deregulated PU.1 expression does appear to aect an aspect of cell division in HMBA treated cells. We believe that the eect is related to the previously described induction of transient G 1 arrest occurring at 12 ± 24 h in MEL cells treated with certain differentiation inducers (Friedman and Schildkraut, 1978; Gambari et al., 1978) including HMBA. We hypothesize that deregulated expression of PU.1 causes a lengthening of HMBA-induced transient G 1 arrest, resulting in delayed growth of colonies in plasma clot. Further experiments are needed to con®rm this view.
Hierarchy of gene expression changes required for MEL cell dierentiation
Deregulated expression of two other protooncogenes, c-myc and c-myb, has also been shown to block chemically-induced dierentiation of MEL cells (Coppola and Cole, 1986; Dmitrovsky et al., 1986; Lachman et al., 1986; Clarke et al., 1988; Prochownik and Kukowska, 1986; McClinton et al., 1990) . As discussed above, the inducer-mediated decline in PU.1 gene expression diers from that of c-myc and c-myb which occurs in two phases separated by a period in which both genes are reexpressed to pretreatment levels prior to or at about the time cells begin to commit to terminal dierentiation (Lachman and Skoultchi, 1984; Ramsay et al., 1986 and Figure 1b) . There is evidence indicating that only the later decline in c-myc and c-myb expression is required for MEL cell terminal dierentiation (Coppola and Cole, 1986; Dmitrovsky et al., 1986; Clarke et al., 1988; Prochownik and Kukowska, 1986; Todokoro et al., 1988; McClinton et al., 1990) . To gain insight into the hierarchy among these gene expression changes we investigated expression of the three genes in transfected cell lines expressing deregulated copies of each of the genes. Figure 4a shows that inducer treatment of MEL transfectants overexpressing either c-myc or c-myb caused a rapid decline in PU.1 mRNA levels like that occurring in treated MEL cells or control G418-well plates at 0.1 ml/well. Plates were incubated at 378C in a humidi®ed CO 2 atmosphere. After 24 h, 0.1 ml of complete growth medium containing 2 mg/ml G418 was added to each well and incubation at 378C continued. At three day intervals, a large fraction of the growth medium was exchanged by aspiration and addition of fresh growth medium containing 1 mg/ml G418. After 10 ± 14 days, clones were transferred to cell culture¯asks and propagated in growth medium containing 1 mg/ml G418. 20 mg of total cellular RNA were analysed by RNase protection assays diagrammed in b. Size markers (M) were obtained by end labeling a MspI digest of pBR322 with [ nd= not determined PU.1 blocks MEL cell differentiation G Rao et al resistant transfectants that do not contain deregulated copies of either gene. Despite the down regulation of PU.1 expression in these lines, they produced very few benzidine-positive cells (Dmitrovsky et al., 1986; Clarke et al., 1988 and data not shown) . This result indicates that HMBA-induced down regulation of PU.1 expression is not sucient to induce differentiation when exogenous copies of c-myc or c-myb genes cause these proteins to be maintained at a high level. In contrast to the absence of an eect of constitutive cmyc or c-myb expression on PU.1 mRNA levels, deregulated expression of PU.1 blocked the second decline in c-myc and c-myb mRNAs (Figure 4b ). These results suggest that PU.1 inhibits an earlier step(s) required for MEL cell dierentiation than that aected by Myc and Myb. Note also that the time of maximal reexpression of c-myc was delayed in inducer treated deregulated PU.1 transfectants. This observation may be related to the retarded colony growth in plasma clot seen with these transfectants, which we speculate may be due to a lengthened transient arrest in G1, possibly caused by delayed reexpression of c-myc.
Concluding remarks
The high frequency (95%) of SFFV insertions at the Spi-1 locus in erythroleukemic clones derived from Friend virus-infected mice suggested that the resulting activation of PU.1 expression plays an important role in immortalization of the tumor cells (Moreau- Paul et al., 1989 Paul et al., , 1991 . The fact that a PU.1-encoding retrovirus can eciently immortalize erythroblasts from long-term bone marrow cultures (Schuetze et al., 1993 ) strongly supports such a role. PU.1 also might interfere with processes required for terminal dierentiation of erythroblasts. The fact that PU.1 mRNA and protein levels (Schuetze et al., 1992; Galson et al., 1993; Delgado et al., 1994 and Figure 1 ) are down regulated during chemicallyinduced MEL cell dierentiation is consistent with this view. The results reported in the present study provide direct evidence that PU.1 can block terminal erythroid dierentiation. We found that maintenance of PU.1 gene expression in pEBB-PU.1 MEL cell transfectants during HMBA treatment caused a marked inhibition of production of heme-positive cells and accumulation of globin mRNA. These transfectants also failed to irreversibly commit to terminal cell division as determined by plasma clot assay. Thus down regulation of PU.1 expression is required for MEL cells to reinitiate their terminal dierentiation program. Furthermore, it appears that MEL cell dierentiation may be quite sensitive to PU.1 levels, since we observed strong inhibition of dierentiation in transfectants expressing levels of the exogenous EF1a ± PU.1 mRNA that were comparable to endogenous PU.1 mRNA levels. This result contrasts with the observed inhibition of MEL cell dierentiation produced by transfected c-myc and c-myb genes which have been expressed at much higher levels than thë Table 1 ) following treatment with 5 mM HMBA for the indicated times were analysed by Northern blot hybridization with a 520 bp fragment of mouse b-globin cDNA derived from pCR1b M G9 (Rougeon and Mach, 1977) . (b) Cell lines (see Table 1 ) were treated with 5 mM HMBA and at the indicated times an aliquot of cells was removed and the percent committed cells was determined by plasma clot assay in the absence of HMBA as described in the legend to Figure  1b corresponding endogenous genes (Coppola and Cole, 1986; Dmitrovsky et al., 1986; Prochownik and Kukowska, 1986; Clarke et al., 1988; McClinton et al., 1990; Shoji et al., 1993) .
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PU.1 is a member of the ets family of transcription factors which bind DNA sequences containing a GGAA core element. Theoretically, PU.1 could interfere with MEL cell dierentiation either directly by inhibiting expression of genes required for terminal dierentiation, or indirectly by stimulating expression of genes that promote cell proliferation, or both. The fact that PU.1 has been shown to regulate transcription of a number of target genes in myeloid cells (Hohaus et al., 1995 and references therein) perhaps argues for a role in stimulating genes in MEL cells required for cell proliferation. The reported interaction between PU.1 and the retinoblastoma tumor suppressor (Rb) protein (Hagemeier et al., 1993) which interacts with several cellular and viral factors that are known to promote cell division also supports this view. Indeed treatment of MEL cells with PU.1 antisense oligonucleotides has been reported to cause partial inhibition of MEL cell proliferation (Delgado et al., 1994) . However, we do not think that PU.1 interferes with MEL cell dierentiation solely by stimulating proliferation of HMBA-treated cells because we observed that the growth rate of pEBB-PU.1 MEL transfectants in the presence of HMBA was actually reduced compared with similarly treated, untransfected MEL cells and control transfectants. Nevertheless, these transfectants do not undergo terminal cell division. The transcriptional transactivation domain and the Rb binding region of PU.1 reside in the amino-terminal end of the molecule, whereas the DNA binding domain is localized to the carboxy-terminal region (Klemsz et al., 1990; Paul et al., 1991; Hagemeier et al., 1993) . Thus using appropriate mutant proteins and the phenotypic assay described here it should be possible to determine which functions of PU.1 are required for inhibition of erythroid dierentiation.
The results reported here also provide some insight into the order of events required for erythroleukemia cells to reinitiate terminal dierentiation. Deregulated expression of any one of three dierent protooncogenes, c-myc, c-myb or PU.1, has now been shown to block MEL cell dierentiation (Coppola and Cole, 1986; Dmitrovsky et al., 1986; Lachman et al., 1986; Prochownik and Kukowska, 1986; Clarke et al., 1988; McClinton et al., 1990; Shoji et al., 1993 and this study) . Expression of all three genes is rapidly down regulated upon exposure of MEL cells to chemical inducers of dierentiation. However, subsequently cmyc and c-myb are reexpressed, followed by a second decline of expression as the cells undergo differentiation (Lachman and Skoultchi, 1984) . Previous studies have indicated that only the second decline in expression of c-myc and c-myb is required for terminal dierentiation (Coppola and Cole, 1986; Dmitrovsky et al., 1986 , 1988) , and a MEL cell line transfected with pSV2neo alone (clone 57, Dmitrovsky et al., 1986) were grown in the presence of 5 mM HMBA. At the times indicated, total cellular RNA was prepared and 20 mg of RNA were analysed by Northern blot hybridization with the 960 bp PU.1 cDNA probe. (b) pEBB-PU.1 MEL transfectants (see Table 1 ) and parental MEL cells were grown in the presence of 5 mM HMBA. At the times indicated, total cellular RNA was prepared and 20 mg of RNA were analysed by Northern blot hybridization with a 2.4 kb EcoRI c-myc cDNA probe (left panel), isolated from p10.10.1 (Bender and Keuhl, 1986) or the cmyc cDNA probe (right panel), described in the legend to Figure 1a 1990), suggesting that the changes in Myc and Myb levels that are crucial for dierentiation are controlled by an earlier step(s) in the program. Our results suggest that one such event is down regulation of PU.1 levels. This conclusion is based on two types of observations:
(1) deregulated expression of PU.1 prevents the late decline (but not the early decline) in endogenous c-myc and c-myb mRNA levels induced by HMBA ( Figure  4b ) and (2) overexpression of c-myc or c-myb does not interfere with the HMBA-induced decline of PU.1 mRNA level (Figure 4a ). We hypothesize that chemical induction of MEL cell dierentiation is triggered by turning o PU.1 gene expression which in turn leads to down regulation of c-myc and c-myb. The speci®city of these inducer-mediated eects on gene expression is supported by the observation that overexpression of cmyc does not interfere with the late decline in c-myb mRNA levels (Bar-Ner et al., 1992) while overexpression of c-myb has been shown to prevent the late decline in c-myc mRNA level (Clarke et al., 1988; McClinton et al., 1990) . Moreover, Myb has been reported to transactivate c-myc (Evans et al., 1990; Zobel et al., 1992; Cogswell et al., 1993) . These additional observations suggest that PU.1 may block MEL cell dierentiation in part by acting through Myb to increase or deregulate c-myc expression. Taken together these observations suggest that MEL cell dierentiation requires a series of steps involving down regulation of protooncogene expression in the order PU.1?c-myb?c-myc.
Note added in proof While our manuscript was in review, Moreau-Gachelin et al., (Mol. Cell. Biol., 1996 , 16, 2453 ± 2463 reported that an SFFV-LTR driven PU.1 transgene induced multistep erythroleukemia in mice.
